Literature DB >> 27746277

Precision targeted therapy of ovarian cancer.

Justin Sapiezynski1, Oleh Taratula2, Lorna Rodriguez-Rodriguez3, Tamara Minko4.   

Abstract

The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic profiling; Nanotechnology; Personalized medicine; Targeted therapy; siRNA

Mesh：

Year:  2016        PMID： 27746277      PMCID： PMC5191987          DOI： 10.1016/j.jconrel.2016.10.014

Source DB:  PubMed          Journal:  J Control Release        ISSN： 0168-3659            Impact factor:   9.776


  142 in total

1.  Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.

Authors:  Iontcho R Vlahov; Hari Krishna R Santhapuram; Paul J Kleindl; Stephen J Howard; Katheryn M Stanford; Christopher P Leamon
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

2.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Authors:  Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula A Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

Review 3.  A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Authors:  M Dietel; K Jöhrens; M V Laffert; M Hummel; H Bläker; B M Pfitzner; A Lehmann; C Denkert; S Darb-Esfahani; D Lenze; F L Heppner; A Koch; C Sers; F Klauschen; I Anagnostopoulos
Journal:  Cancer Gene Ther       Date:  2015-09-11       Impact factor: 5.987

4.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

5.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  Multiplexed ion beam imaging of human breast tumors.

Authors:  Michael Angelo; Sean C Bendall; Rachel Finck; Matthew B Hale; Chuck Hitzman; Alexander D Borowsky; Richard M Levenson; John B Lowe; Scot D Liu; Shuchun Zhao; Yasodha Natkunam; Garry P Nolan
Journal:  Nat Med       Date:  2014-03-02       Impact factor: 53.440

7.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

8.  Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Authors:  Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

9.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

10.  The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.

Authors:  Michael Eichbaum; Christine Mayer; Regina Eickhoff; Esther Bischofs; Gerhard Gebauer; Tanja Fehm; Florian Lenz; Hans-Christian Fricke; Erich Solomayer; Nikos Fersis; Marcus Schmidt; Markus Wallwiener; Andreas Schneeweiss; Christof Sohn
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430
View more
  18 in total

1.  Cervical Evaluation: From Ancient Medicine to Precision Medicine.

Authors:  Helen Feltovich
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.661

Review 2.  Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.

Authors:  Bruna Corradetti; Simone Pisano; Robert Steven Conlan; Mauro Ferrari
Journal:  J Pharmacol Exp Ther       Date:  2019-02-08       Impact factor: 4.030

Review 3.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

Review 4.  A review on core-shell structured unimolecular nanoparticles for biomedical applications.

Authors:  Guojun Chen; Yuyuan Wang; Ruosen Xie; Shaoqin Gong
Journal:  Adv Drug Deliv Rev       Date:  2018-07-20       Impact factor: 15.470

Review 5.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

6.  Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.

Authors:  Lu Xu; Qi Xie; Ling Qi; Chunyan Wang; Na Xu; Weimin Liu; Yang Yu; Songyan Li; Ye Xu
Journal:  Oncol Rep       Date:  2017-12-19       Impact factor: 3.906

7.  Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.

Authors:  Felicitas Mungenast; Stefanie Aust; Ignace Vergote; Adriaan Vanderstichele; Jalid Sehouli; Elena Braicu; Sven Mahner; Dan Cacsire Castillo-Tong; Robert Zeillinger; Theresia Thalhammer
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

8.  LncRNA CTBP1-AS2 regulates miR-216a/ PTEN to suppress ovarian cancer cell proliferation.

Authors:  Kaiying Cui; Genhai Zhu
Journal:  J Ovarian Res       Date:  2020-07-25       Impact factor: 4.234

9.  Klotho promoter methylation status and its prognostic value in ovarian cancer.

Authors:  Maryam H Al-Zahrani; Fatimah M Yahya; Mourad Assidi; Ashraf Dallol; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2021-07-03

10.  Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer.

Authors:  Kejin Huang; Jiashi Geng; Jing Wang
Journal:  Cancer Sci       Date:  2018-04-29       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.